CustomCustomCustomCustomCustomCustom
22 10, 2024

Webinar Announcement

2024-10-22T08:18:05+02:00October 22nd, 2024|biomarker, Biomarker Discovery, biomarkers, microRNAs, NGS, small RNA-sequencing|0 Comments

🔬 Join us for an insightful webinar on transcriptomics where we will delve into cutting-edge strategies for biomarker discovery, basic research, and translational applications. Whether you're focused on diagnostics or overcoming the challenges of low-input sample analysis, this webinar is designed for you! Title: Harnessing Transcriptomics: microRNA and mRNA analysis for Biomarker Discovery, Basic Research, and Translational Applications What to Expect: Comprehensive Transcriptomics Sequencing Services tailored to your research needs Insights into Biomarker Discovery, driving breakthrough advancements in diagnostics Strategies to overcome challenges with low-input samples, including biofluids and extracellular vesicles Opportunity to connect with our experts to discuss your transcriptomics goals and potential collaborations 📅 Date: 7.11.2024 🕒 Time: 14:00 -15:00 CET Presentation by Matthias Hackl, [...]

Read More
17 10, 2024

TAmiRNA at Precision EV Forum in Cambridge

2024-10-17T12:39:26+02:00October 17th, 2024|biomarker, biomarkers, Evercyte, EVscale, microRNAs, NGS, small RNA-sequencing|0 Comments

Excited to share that TAmiRNA and Evercyte will join forces at the upcoming Precision EV Forum in Cambridge! 🚀 As key members of the EVscale® consortium, they’ll be showcasing cutting-edge solutions in EV (extracellular vesicles) characterization and therapeutics. TAmiRNA will present its advanced multiomic capabilities for RNA cargo characterization, aiding in biomarker discovery. Evercyte will highlight its clinical-grade EVs produced from telomerized MSCs, demonstrating the potential of EV therapeutics. Together with Phoenestra's bioreactor technology, these innovations support faster, scalable EV production. 🌱🧬 Catch us at Cripps Court Conference Centre and discover our vision for the future of EV-based precision medicine! 💡🔬 Meet us at the Precision EV Forum or reach out to info@tamirna.com to discuss our latest [...]

Read More
15 10, 2024

Eager to lern more about differential miRNA expression patterns in Type 2 diabetes mellitus

2024-10-15T07:46:12+02:00October 15th, 2024|biomarker, bone diseases, bone fracture risk assessment, diabetes, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA|0 Comments

Excited to share our latest study on the link between Type 2 Diabetes Mellitus (T2DM) and bone fragility using miRNA profiling in a polygenic mouse model! 🧬🦴 🔍 Research Highlights: We utilized an unbiased genome-wide approach to identify dysregulated miRNAs in serum, bone marrow, and bone of the TallyHo/JngJ (TH) mouse model, which closely mirrors T2DM in humans. Key findings include upregulation of miRNAs such as mmu-miR-466i-5p and mmu-miR-1195 in both serum and bone marrow of diabetic mice. Dysregulated miRNAs were linked to pathways associated with diabetes-related signaling and diabetic bone disease, shedding light on potential mechanistic pathways. Cell-type enrichment analysis pointed towards miRNAs enriched in specific cell types like immune cells, hepatocytes, and mesenchymal stem cells, [...]

Read More
7 10, 2024

Celebrating the Nobel Prize in Physiology or Medicine 2024!

2024-10-07T14:06:06+02:00October 7th, 2024|biomarker, biomarkers, hepatomiR kit, microRNAs|Comments Off on Celebrating the Nobel Prize in Physiology or Medicine 2024!

Congratulations to Victor Ambros and Gary Ruvkun, this year’s Nobel Laureates, for their pioneering discovery of microRNAs—tiny but powerful molecules that regulate gene expression and have reshaped our understanding of biology, aging, cancer, and development. At TAmiRNA, we’ve been deeply inspired by this breakthrough and have dedicated over 10 years to harnessing the potential of microRNAs. We’ve developed cutting-edge diagnostic tools that leverage microRNAs as biomarkers, with our regulatory approved hepatomiR® device leading the way in improving liver cancer patient care across Europe. Our passion for innovation has resulted in over 100 scientific publications, and we’re proud to contribute to advancing this transformative field. The Nobel Prize serves as a reminder of the impact that these discoveries can [...]

Read More
27 09, 2024

TAmiRNA at the GSEV 2024 Scientific Conference

2024-09-27T09:11:28+02:00September 27th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, Illumina NewSeq2000, microRNAs, miND, NGS, small RNA-sequencing|Comments Off on TAmiRNA at the GSEV 2024 Scientific Conference

We are thrilled to announce that TAmiRNA will contribute a poster at the upcoming German Society for Extracellular Vesicles (GSEV) Autumn Meeting 2024, presenting our recent advancements in the biodistribution of extracellular vesicles (EVs). The poster will be presented by our expert, Magdalena Mecking. Don’t miss this opportunity to explore TAmiRNA's latest advancements regarding transcriptomic characterization of EVs. Meet Magdalena at the GSEV or reach out to info@tamirna.com to discuss our latest developments and how TAmiRNA’s  services for EV characterization can assist your business! Click here to read the press release. TAmiRNA Scientific Consultant Magdalena Mecking

Read More
18 09, 2024

Eager to lern more about neuron-derived extracellular vesicles as predictive biomarkers

2024-09-18T14:10:09+02:00September 18th, 2024|biomarker, biomarkers, exosomes, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA|Comments Off on Eager to lern more about neuron-derived extracellular vesicles as predictive biomarkers

A new study from the University of Trieste explores the potential of microRNA (miRNA) profiles in neuron-derived extracellular vesicles (NDEVs) as predictive biomarkers for adverse drug reactions (ADRs) in children receiving ketamine. This research, leveraging TAmiRNA's Next-Generation Sequencing (NGS)-based miND® pipeline, identified specific miRNAs (miR-18a-3p, miR-484, and miR-548az-5p) as potential tools to predict ketamine-induced ADRs. This breakthrough not only advances our understanding of ketamine's side effects in children but also demonstrates the biomarker potential of organ-specific EVs and their miRNA cargo. Interested in our of extracellular vesicles (EVs) and exosomes services - click here! click here to read the paper

Read More
11 09, 2024

TAmiRNA at ASEV/CzeSEV meeting

2024-09-11T14:41:44+02:00September 11th, 2024|biomarker, biomarkers, Evercyte, EVscale, microRNAs, NGS, Phoenestra, small RNA-sequencing|Comments Off on TAmiRNA at ASEV/CzeSEV meeting

TAmiRNA, Evercyte and Phoenestra, three leading biotech companies, will present their cutting-edge work in for production and characterization of clinical-grade extracellular vesicles (EVs) at the upcoming shared Annual Meeting of the Austrian and Czechia Societies for Extracellular Vesicles (ASEV & CzeSEV) on 16th/17th September in Vienna. As esteemed ASEV members, TAmiRNA and Evercyte are well-known participants at these meetings and this year will take the spotlight as Platinum Sponsors. They will be joined by Phoenestra in this sponsorship as part of the EVscale™ Partnership, showcasing their joint capabilities and innovation in EV research and development. Don’t miss this opportunity to explore TAmiRNA's latest advancements regarding transcriptomic characterization of EVs. Meet us at the ASEV or reach out to [...]

Read More
6 09, 2024

TAmiRNA at EUROTOX 2024 in Copenhagen

2024-09-11T08:35:27+02:00September 6th, 2024|biomarker, biomarkers, drug-induced pancreatic injury, microRNAs, miND, miND spike ins, NGS, small RNA-sequencing, TransBioLine|Comments Off on TAmiRNA at EUROTOX 2024 in Copenhagen

On September 10, our CEO & CSO, Dr. Matthias Hackl, will discuss “Small RNA-sequencing based discovery of microRNAs for CNS-injury biomarkers” during the EUROTOX Short Orals Session. He’ll highlight the efforts of TAmiRNA and the IMI consortium TransBioLine in advancing microRNAs as biomarkers of drug-induced brain injury. TAmiRNA will also bring a poster (P06-01) to the conference, authored by Senior Scientist, Dr. Kseniya Khamina-Kotisch, on “NGS-based discovery of microRNA biomarkers of drug-induced pancreatic injury (DIPI),” showcasing the merits of small RNA-sequencing (miND) for biomarker discovery. Don’t miss this opportunity to explore TAmiRNA's latest advancements in microRNA diagnostics. Reach out to Matthias directly to meet and discuss our latest developments and how TAmiRNA's  services can assist your business! TAmiRNA [...]

Read More
2 09, 2024

TAmiRNA at SSCC/SGK in Zürich

2024-09-11T08:36:01+02:00September 2nd, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNAs, miND spike ins, NGS|Comments Off on TAmiRNA at SSCC/SGK in Zürich

TAmiRNA will spotlight its miND® NextGen small RNA-sequencing platform and the hepatomiR® test—Europe's first CE-IVD marked test for liver function microRNA biomarkers—at the Zürich conference. These innovations highlight TAmiRNA's strengths in microRNA diagnostic development. Dr. Matthias Hackl, CEO and Chief Scientific Officer, will present "MicroRNAs as a Novel Class of Biomarkers" on Friday, September 6, in Session 6: New Technologies. He will discuss the critical role of miRNA biomarkers and TAmiRNA's advanced sequencing techniques, which speed up the discovery of novel biomarker associations. Don’t miss this opportunity to explore TAmiRNA's latest advancements in microRNA diagnostics. Reach out to Matthias directly to meet and discuss our latest developments and how TAmiRNA's  services can assist your business! TAmiRNA [...]

Read More
9 08, 2024

Eager to lern more about Early Detection of Colorectal Cancer through MicroRNA Profiling

2024-08-09T11:17:20+02:00August 9th, 2024|biomarker, biomarkers, exosomes, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA|Comments Off on Eager to lern more about Early Detection of Colorectal Cancer through MicroRNA Profiling

TAmiRNA and its partner Biomedica are proud to announce that researchers from the Jagiellonian University Medical College used our innovative small RNA-sequencing pipeline (miND®) to unravel novel miRNA expression profiles in colorectal cancer cell lines and the extracellular vesicles (EVs) they produce. Colorectal cancer ranks as the third most common cancer in men and the second in women globally. Late diagnosis significantly contributes to rising morbidity and mortality rates, emphasizing the urgent need for new markers for early and precise detection. The analysis of miRNAs in plasma-derived EVs and tumor samples from CRC patients revealed a similar miRNA expression profile between patient samples and CRC cell lines. Importantly, miR-182-5p, miR-196b-5p, miR-425-5p, and miR-429 were found regulated in [...]

Read More
© Copyright TAmiRNA 2019 - 
 
Go to Top